Discovery of novel 2,4-diarylaminopyrimidine derivatives as FAK inhibitors with potent anti-cancer potency
Key Points
The study aims to evaluate 2,4-diarylaminopyrimidine derivatives as FAK inhibitors for cancer treatment.
Synthesis of novel compounds
Testing selectivity against FAK
Assessing antitumor activity
Comparative analysis of lead candidate
Compound D12 shows improved selectivity for FAK
Demonstrates potent antitumor activity
Represents a promising candidate for cancer therapy
Abstract
Compound D12 is a novel FAK inhibitor with improved selectivity and potent antitumor activity, representing a promising lead candidate for cancer therapy.